Europe
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
This morning, Dublin-based Amryt said the primary endpoint of the late-stage study was met. Look at what else the phase III trial of Filsuvez depicted.
AstraZeneca paused its Phase III COVID-19 vaccine trial following a report of an “unexplained illness” in a patient involved in the study.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran.
Results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.
Ai in medical field is helping the researchers at clinical stage research by increasing the efficiency, refining endpoints and quantifying pain, and much more.
PRESS RELEASES